LF 181505
Alternative Names: LF181505Latest Information Update: 27 Jul 2007
Price :
$50 *
At a glance
- Originator Fournier Pharma
- Class
- Mechanism of Action Bradykinin B2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 27 Jul 2007 Discontinued - Preclinical for Stroke in France (IV)
- 28 Jul 2005 Fournier-Pharma has been acquired by Solvay
- 02 Apr 2001 Preclinical development for Stroke in France (IV)